124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial.

MLA

Lane, R., et al. “124P Acquired Resistance to First-Line Chemo- and EGFRab-Therapy in MCRC: Biopsy Analysis of the ISCORE Trial.” Annals of Oncology, vol. 35, June 2024, p. S58. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.05.135.

APA

Lane, R., Mencel, J., Turkes, F., Challoner, B. R., McCafferty, N., Ntellas, P., Barber, L. J., Rana, I., Chen, H.-C., Begum, R., Ficial, M., Tran, A., Terlizzo, M., Rao, S., Cunningham, D., Chau, I., Starling, N., & Gerlinger, M. (2024). 124P Acquired resistance to first-line chemo- and EGFRab-therapy in mCRC: Biopsy analysis of the iSCORE trial. Annals of Oncology, 35, S58. https://doi.org/10.1016/j.annonc.2024.05.135

Chicago

Lane, R., J. Mencel, F. Turkes, B.R. Challoner, N. McCafferty, P. Ntellas, L.J. Barber, et al. 2024. “124P Acquired Resistance to First-Line Chemo- and EGFRab-Therapy in MCRC: Biopsy Analysis of the ISCORE Trial.” Annals of Oncology 35 (June): S58. doi:10.1016/j.annonc.2024.05.135.